Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open Label Study of CB7630 (Abiraterone Acetate) and Prednisone in Patients With Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy

NCT00485303 is registered in ClinicalTrials.gov with Cougar Biotechnology, Inc. as lead sponsor.

NCT NCT00485303
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00485303 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open Label Study of CB7630 (Abiraterone Acetate) and Prednisone in Patients With Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
Lead sponsor
Cougar Biotechnology, Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2007
Completion date
October 31, 2011
Enrollment
58 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer, prostatic neoplasms